Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Dantrium 100 mg Capsules

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Dantrolene sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Dantrolene sodium
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Dantrium is a medicine that reduces increased muscle tension. Dantrium is used for spastic movement disorders with abnormally increased muscle tension due to various causes in adults and children over the age of 5 years old weighing 25 kg or more.

What you need to know before you take it

e Dantrium Capsules

Do not take Dantrium

  • if you are allergic to dantrolene sodium 3.5 H2O, or any of the other ingredients of this medicine (listed in section 6), –

if you have liver disease, –

in cases where abnormally increased muscle tension is required to improve function, posture or movement balance,

–

if you have impaired lung function,

–

if you have severe heart muscle damage,

–

if you are pregnant or breast-feeding,

–

If you are allergic (hypersensitive) to wheat, due to the presence of wheat starch.

Warnings and precautions Talk to your doctor or pharmacist before taking Dantrium.

1

Take special care with Dantrium

  • if you suffer from amyotrophic lateral sclerosis (ALS, a disorder of the nervous system), if you have symptoms of bulbar paralysis (symptoms caused by damage to certain cranial nerves), as Dantrium can exacerbate symptoms of paralysis, –

if you have heart disease, particularly heart damage and/or heart arrhythmia. Your doctor will carefully monitor you for heart disease.

Before and during treatment with Dantrium your doctor will carry out regular blood tests to check your liver function. If the values are outside the normal range, treatment with Dantrium must be discontinued. If you notice any signs that might indicate liver damage, such as unusual fatigue, light stools, itching all over the body, yellowing of the skin or eyes, loss of appetite, nausea and vomiting, you should seek medical attention immediately. The risk of liver damage appears to be particularly high at daily doses of more than 300 mg, with prolonged treatment, in female patients over 30 years of age, with a history of liver damage and concomitant use of other medicines that can cause liver damage. Liver damage can be life-threatening, especially in the elderly. If you suffer from multiple sclerosis, the risk of serious liver damage appears to be even higher. Dantrium may cause the skin to become sensitive to light (photosensitisation), so you should protect yourself from strong sunlight during treatment. Administration of Dantrium must be discontinued if patients have developed cardiac and pleural reactions with fluid accumulation (pleural or pericardial effusion or pleuropericarditis). Doses of more than 200 mg dantrolene per day are more likely to cause side effects. This medicine contains only very low levels of gluten (from wheat starch). It is regarded as 'glutenfree' and is very unlikely to cause problems if you have coeliac disease. One Dantrium 25mg capsule contains no more than 3.8 micrograms of gluten. One Dantrium 100mg capsule contains no more than 3.3 micrograms of gluten. Children Dantrium can be used in children over 5 years of age under supervision from your doctor. Dantrium should not be given to children under 5 years of age as there is insufficient experience with the use of Dantrium in this patient group to determine tolerability. Other medicines and Dantrium Tell your doctor or pharmacist if you are taking/using or have recently taken/used any other medicines, even if they are not prescription medications. If taken at the same time as –

oestrogens (certain hormones) or other potentially liver-damaging substances there is an increased risk of liver damage,

–

vecuronium (muscle relaxant drug) its effect can be amplified,

–

metoclopramide (a medicine used to treat certain gastrointestinal disorders), the absorption of the active ingredient of Dantrium in the body may be increased, leading to an increase in the effect and side effects of dantrolene.

2

Simultaneous use of medicines that depress the central nervous system (sedatives, such as benzodiazepines, antihistamines) and alcohol is to be avoided as the side effects of Dantrium may be increased (in particular the central nervous system depressant effect and muscle weakness). In patients predisposed to malignant hyperthermia (certain complications of anaesthesia) who received intravenous dantrolene, it has been observed that simultaneous administration of calcium antagonists and/or beta-blockers (antihypertensive/heart disease drugs) resulted in elevated potassium levels and cardiac insufficiency. Dantrium with food and drink Do not drink alcohol while taking Dantrium. Pregnancy and breast-feeding Dantrium should not be used during pregnancy, as the safety of Dantrium for use during pregnancy has not been established. The active substance of Dantrium passes into breast milk. Dantrium should not be used while breastfeeding, since adverse effects on the breastfed child cannot be excluded, particularly under long-term treatment with Dantrium. Breast-feeding must be discontinued if treatment is required while breastfeeding. Ask your doctor or pharmacist for advice before taking/using any medicine. Driving and using machines You must not drive or operate machinery without consulting your doctor. When Dantrium or other medicines that also affect the central nervous system are taken at the same time, central nervous system effects, such as drowsiness or confusion, can change the ability to react to such an extent that it reduces the ability to drive or operate tools and machines. This particularly applies at the start of treatment, when dosage is increased and when taken together with alcohol. Dantrium Capsules contain lactose and wheat starch. This medicine contains lactose and wheat starch. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking this medicine.

How to take it

Dantrium Capsules Always take Dantrium exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will slowly adjust the number of capsules you take until the optimal dose required for your treatment is reached. The lowest dose compatible with optimal response is recommended. Adults Unless prescribed otherwise by your doctor, the usual dose for adults at the beginning of treatment is 1 capsule daily. This dose should be increased weekly until the optimal dose is reached. The dose should not be increased faster than as per the following schedule: Week 1: 1 Dantrium 25 mg capsule once a day Week 2: 1 Dantrium 25 mg capsule two times a day

3

Week 3: 2 Dantrium 25 mg capsules two times a day Week 4: 2 Dantrium 25 mg capsules three times a day Once the optimal dose is reached, the patient should take their total daily dose subdivided between 2 to 4 individual doses. Doses of more than 200 mg should not be given in long-term Dantrium treatment, as doses of more than 200 mg of dantrolene per day are more likely to result in side effects. If it is foreseeable that the patient will face stress or stressful situations, the dose can be increased temporarily and gradually up to 400 mg per day. The increased dose should be titrated as follows: Week 5: 75 mg three times a day Week 6: 75 mg four times a day Week 7: 100 mg four times a day Doses of more than 200 mg per day should not be given for more than 2 months.

Children Unless prescribed otherwise by your doctor, the following dosage should be used for children aged 5 years and older (from 25 kg body weight): Week 1: 1 Dantrium 25 mg capsule once a day Week 2: 1 Dantrium 25 mg capsule two times a day Week 3: 1 Dantrium 25 mg capsule three times a day Week 4: 2 Dantrium 25 mg capsules two times a day Week 5: 2 Dantrium 25 mg capsules three times a day Week 6: 3 Dantrium 25 mg capsules three times a day Children weighing 50 kg or more: See dosage for adults. The dose can be gradually increased up to 200 mg daily. Please take the capsules whole with plenty of liquid (preferably with a glass of water). If no improvement is achieved after a total of 6-8 weeks, treatment should be discontinued by the doctor. Please talk to your doctor or pharmacist if you feel that the effect of Dantrium is too strong or too weak. If you take more Dantrium than you should Tell your doctor immediately. He or she will take the necessary measures. Signs of overdose may include disorders of consciousness (e.g. lethargy, coma), muscle weakness, fatigue, dizziness, weakness, impaired vision, rapid heartbeat, itching, loss of appetite, nausea, vomiting, diarrhoea, light stools, yellowing of the skin or eyes.

4

If you forget to take Dantrium Do not take a double dose to make up for an omitted dose. Take the same number of capsules as prescribed, when your next dose is due. If you are unsure what to do, please talk to your doctor. If you stop taking Dantrium If you temporarily want to stop treatment or stop it early, e.g. because the side effects appear too severe, please talk to your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The frequencies for the following list of adverse drug reactions are based on estimates after reports of adverse drug reactions to the approved drug. Very common (may affect more than 1 in 10 people): Fatigue, weakness, malaise, dizziness, drowsiness and diarrhoea. In persistent diarrhoea, the medicinal product must be discontinued. Common (may affect up to 1 in 10 people): In patients treated with Dantrium, the following occurred: Headache, speech disorders, seizures, loss of appetite, impaired vision, abdominal cramps, nausea, vomiting, skin rashes, acne-like skin reactions, muscle weakness, which may cause functional impairment and coordination disorders, chills, fever, depression, confusion, nervousness, insomnia, respiratory failure, abnormal liver function test, liver damage: even daily doses of up to 200 mg can cause liver-damaging side effects, usually as inflammation of the liver with jaundice. Uncommon (may affect up to 1 in 100 people): In patients treated with Dantrium, the following occurred: Reduction of red blood cells due to impaired or lack of production (aplastic anaemia), reduction of white blood cells (leukopaenia), lymph node cancer (lymphocytic lymphoma), thrombocytopaenia, allergic reaction, acute allergic reaction (anaphylaxis), hallucinations, triggering of cerebral seizures, particularly in children with cerebral palsy; aggravation of paralysis in amyotrophic lateral sclerosis (ALS, a disorder of the nervous system) or presence of symptoms of bulbar paralysis (symptoms caused by damage to certain cranial nerves). Double vision, increased tear-flow, increased heart rate, insufficient cardiac output (heart failure); phlebitis, fluctuations in blood pressure, constipation, in rare cases including intestinal obstruction; difficulty swallowing, taste disorders, shortness of breath, bleeding in the gastrointestinal tract, abdominal pain, increased salivation. Increased sweating, abnormal hair growth, itching, photosensitivity, muscle and back pain, excretion of crystals or red blood cells in the urine (crystalluria, haematuria), involuntary urinary incontinence, urinary retention or increased urinary frequency, Cardiac and pleural reactions with fluid accumulation (pleural or pericardial effusion or pleuropericarditis), accompanied by eosinophilia (proliferation of certain cells in the blood) has been reported, as well as respiratory disorders, presumably due to weakening of the respiratory muscles. Very Rare Feeling of suffocation, skin rash with red swollen bumps, eczema, Micturition disorder, erectile dysfunction. Not known (frequency cannot be estimated from the available data): Decreased heart rate, disorientation. Reduced muscle tone, dry mouth, nocturnal urination (nocturia), discoloured urine, indigestion.

5

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

How to store it

Dantrium Capsules Keep out of the sight and reach of children. Store capsules in the blister and outer packaging away from light and moisture. Do not take Dantrium Capsules after the expiry date which is stated on the outer carton and the blister after "Exp". The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Contents of the pack and other information

What Dantrium Capsules contain

  • The active substance is dantrolene sodium, 25 mg or 100 mg per capsule.
  • The other ingredients are: lactose monohydrate, wheat starch, talcum and magnesium stearate (see section 2).
  • The capsule shell of Dantrium 25mg and 100mg capsules contains gelatine and colouring agents titanium dioxide (E171), erythrosine (E127) and iron oxide (E172). What Dantrium Capsules look like and contents of the pack:
  • Dantrium 25 mg Capsules: The capsules are light brown/orange. They are packed in blisters and available in packs of 100 hard capsules.
  • Dantrium 100 mg Capsules: The capsules are orange/orange. They are packed in blisters and available in packs of 100 hard capsules. Marketing Authorisation Holder: Norgine Pharmaceuticals Limited ARC Uxbridge, Building 01, Sanderson Road, Uxbridge, UB8 1DH, UK Manufacturer: Delpharm L'Aigle Zone Industrielle No1 Route De Crulai 61300 L'Aigle Other sources of information If you need further information on this leaflet in an alternative format please ring 0800 198 5000.

6

This leaflet was last revised in 03/2025.

7

Frequently asked questions about Dantrium 100 mg Capsules

How do I take Dantrium 100 mg Capsules?

Dantrium 100 mg Capsules comes as capsule containing 100mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Dantrium 100 mg Capsules?

The active substance in Dantrium 100 mg Capsules is dantrolene sodium.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Dantrium 100 mg Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Dantrium 100 mg Capsules without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Dantrolene sodium (3 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Dantrium capsules are indicated for the treatment of chronic, severe spasticity of skeletal muscle resulting from disorders such as stroke, spinal cord injury, cerebral palsy and multiple sclerosis in adults and children over the age of 5 years old weighing 25 kg or more.

4.2. Posology and method of administration

Posology

Each patient should be slowly titrated to the required individual dose. For the individual patient the lowest dose compatible with optimal response is recommended. A recommended dosage increment scale is shown below.

Adults:

Dantrium should be titrated no more rapidly than as per the following schedule:

Week 1:

Week 2:

Week 3:

Week 4:

25 mg once a day

25 mg two times a day

50 mg two times a day

50 mg three times a day

As soon as the optimal dose is reached, patients should receive their total daily dose divided over 2 to 4 individual doses to achieve as uniform plasma levels as possible and to minimise adverse reactions.

Doses higher than 200 mg should not be administered in long-term therapy with Dantrium. Temporarily, the dose can be gradually increased up to 400 mg per day if pressurised or stressful situations are anticipated in the patient. The increased dose should be titrated as follows:

Week 5:

Week 6:

Week 7:

75 mg three times a day

75 mg four times a day

100 mg four times a day

However, doses above 200 mg per day should not be given for more than 2 months.

Paediatric Population

Dosing table for children over 5 years (upwards of 25 kg body weight) For the individual patient the lowest dose compatible with optimal response is recommended. A recommended dosage titration schedule is provided below.

Week 1:

Week 2:

Week 3:

Week 4:

Week 5:

Week 6:

1 Dantrium 25mg capsule once a day

1 Dantrium 25mg capsule two times a day

1 Dantrium 25mg capsule three times a day

2 Dantrium 25mg capsules two times a day

2 Dantrium 25mg capsules three times a day

3 Dantrium 25mg capsules three times a day

For children weighing 50 kg or more, see dosage for adults.

The dose can be increased gradually up to 200 mg daily.

Dantrium is intended for long-term therapy.

If therapeutic success is still absent after 6 - 8 weeks of treatment, therapy should be discontinued.

As there is insufficient experience with the use of Dantrium in children under 5 years to assess its tolerability, it should not be used in this patient group.

Method of administration

For oral use.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Hepatic disorders,

- Impaired respiratory function

- Severe impaired cardiac function due to myocardial disease

- In cases where abnormally increased tone is required to allow better function, an upright posture or balance during movement

- Pregnancy and breastfeeding (see section 4.6)

- Wheat allergy (other coeliac disease) (see section 4.4).

4.4. Special warnings and precautions for use

Dantrium must be used with caution in the following situations:

In cases of amyotrophic lateral sclerosis or in the presence of bulbar paralytic symptoms, as paresis can be enhanced by Dantrium.

Patients with cardiac disease, especially in patients with myocardial damage and/or cardiac arrhythmias, must receive particular medical surveillance.

Dantrolene leads to mild to severe liver damage in about 9 out of 100,000 treated patients, in whom mortality affects 10 to 20%.

The risk of liver damage seems to be particularly increased at daily doses higher than 300 mg, during prolonged therapy, in women, in patients over 30 years of age or with a history of liver damage and during concomitant use of other medicinal products that can damage the liver. Liver damage may run a lethal course, especially in elderly patients. In patients suffering from multiple sclerosis, the risk of serious liver damage seems to be further increased.

Before the start and during therapy with Dantrium, liver enzymes must be monitored at regular intervals; in particular, SGOT and SGPT must be monitored frequently. Patients in whom the risk of liver damage is increased must receive particularly close monitoring. If values are outside the norm or if symptoms of liver damage occur, Dantrium must be discontinued.

There are indications that, when liver damage occurs, high serum bilirubin levels correlate to severe progression.

To reduce the risk of liver damage, the lowest possible effective dantrolene dose must be used.

Dantrium can cause photosensitisation; patients should therefore protect themselves against strong sunlight during treatment.

Dantrium must be discontinued if patients have developed pleural or pericardial effusion or pleuropericarditis.

Patients with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take Dantrium.

At doses above 200 mg dantrolene per day, increased adverse reactions must be anticipated.

This medicine contains only very low levels of gluten (from wheat starch). It is regarded as 'gluten-free' and is very unlikely to cause problems in case of coeliac disease.

One capsule contains no more than 3.3 micrograms of gluten.

4.5. Interaction with other medicinal products and other forms of interaction

Concomitant intake of CNS depressants (such as benzodiazepine-type tranquillisers, antihistamines, sedatives) and alcohol consumption should be avoided, as the adverse reactions to Dantrium may be increased (particularly the depressant effect on the central nervous system and muscle weakness).

With concomitant administration of:

-oestrogens or other potentially hepatotoxic substances, there is an increased risk of liver damage.

-Dantrium and non-depolarising muscle relaxants (vecuronium), its effect can be enhanced.

-metoclopramide, the rate and speed of dantrolene absorption may be increased and thus lead to an increase in the effect and undesirable effects of dantrolene.

In patients predisposed to malignant hyperthermia who were receiving intravenous dantrolene, it was observed that co-administration of calcium antagonists and/or beta-blockers led to hyperkalaemia and heart failure.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of dantrolene sodium in pregnant women. Dantrolene crosses the placenta and can induce muscle hypotonia, especially in the uterus. Studies in animals are insufficient with respect to reproductive toxicity (see section 5.3). The use of Dantrium during pregnancy is contraindicated.

Breastfeeding

Dantrium is contraindicated during breastfeeding, as the active substance, dantrolene, is excreted in human milk and undesirable effects on the breast-fed infant cannot be excluded, particularly during long-term therapy with Dantrium. If treatment of nursing mothers with Dantrium is required, breastfeeding must be discontinued.

Fertility

There is no data on the effects of dantrolene on fertility in humans.

4.7. Effects on ability to drive and use machines

During oral use of Dantrium, central nervous effects such as drowsiness or confusion can alter responsiveness to such an extent that the ability to drive actively or operate tools and machinery is reduced. This applies particularly at the start of treatment, when increasing the dose and in combination with alcohol or other medicinal products that depress the central nervous system.

4.8. Undesirable effects

Tabulated list of adverse reactions

System Organ Class

Frequency

Adverse Drug Reactions

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Uncommon

Lymphocytic lymphoma

Uncommon

Lymphoma

Blood and lymphatic system disorders

Uncommon

Aplastic anaemia

Uncommon

Anaemia

Uncommon

Leukopenia

Uncommon

Thrombocytopenia

Immune system disorders

Uncommon

Hypersensitivity

Uncommon

Anaphylactic reaction

Metabolism and nutrition disorders

Common

Decreased appetite

Psychiatric disorders

Common

Depression

Common

Confusional state

Common

Nervousness

Uncommon

Hallucination

Common

Insomnia

Unknown

Disorientation

Nervous system disorders

Very common

Dizziness

Very common

Somnolence

Common

Headache

Common

Speech disorder

Common

Seizures

Uncommon

Enhanced paresis in cases of amyotrophic lateral sclerosis or in the presence of bulbar paralytic symptoms

Uncommon

Dysgeusia

Unknown

Hypotonia

Eye disorders

Uncommon

Diplopia

Uncommon

Lacrimation increased

Common

Visual impairment

Cardiac disorders

Uncommon

Tachycardia

Uncommon

Cardiac failure

Common

Pericarditis

Uncommon

Pleuropericarditis

Unknown

Bradycardia

Vascular disorders

Uncommon

Phlebitis

Uncommon

Blood pressure fluctuation

Respiratory, thoracic and mediastinal disorders

Common

Respiratory depression

Common

Respiratory failure

Very rare

Suffocation feeling

Uncommon

Dyspnoea

Gastrointestinal disorders

Very Common

Diarrhoea

Common

Abdominal cramps

Common

Nausea

Common

Vomiting

Uncommon

Constipation (rarely progressing to signs of intestinal obstruction)

Uncommon

Dysphagia

Uncommon

Gastrointestinal haemorrhage

Uncommon

Abdominal pain upper

Uncommon

Salivary hypersecretion

Unknown

Dyspepsia

Unknown

Dry Mouth

Hepatobiliary disorders

Common

Hepatotoxicity/hepatitis

Common

Jaundice

Common

Cholestasis

Skin and subcutaneous tissue disorders

Common

Rash

Common

Dermatitis acneiform/acne like rash/acne

Uncommon

Hyperhidrosis

Uncommon

Hair growth abnormal

Uncommon

Pruritus

Uncommon

Photosensitivity reaction

Very rare

Urticaria

Very rare

Eczema

Musculoskeletal and connective tissue disorder

Common

Muscular weakness

Uncommon

Back pain

Uncommon

Myalgia

Renal and urinary disorders

Uncommon

Urinary incontinence

Uncommon

Pollakiuria

Uncommon

Crystalluria

Uncommon

Haematuria

Uncommon

Urinary retention

Unknown

Nocturia

Very rare

Micturition disorder

Unknown

Chromaturia

Reproductive system and breast disorders

Very rare

Erectile dysfunction

General disorders and administration site conditions

Very common

Fatigue

Very common

Malaise

Common

Chills

Common

Pyrexia

Very common

Asthenia

Investigations

Common

Liver function tests abnormal

In addition, the following specific undesirable effects have been noticed with the use of Dantrium Capsules:

- Precipitation of cerebral seizures, especially in children with cerebral palsy;

- pleuropericarditis and pericardial effusion, (accompanied by eosinophilia)

- pleural effusion (with associated eosinophilia),

- Diarrhoea (may be severe and may necessitate temporary withdrawal of dantrolene therapy).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms which may occur in case of overdose are: muscular weakness, troubling hypotonia vision disorders (diplopia), changes in consciousness (lethargy, coma), fatigue, dizziness, vomiting, diarrhoea, tachycardia, hypo- or hypertension, pruritus, adverse hepatotoxic reactions.

In case of intoxication, if possible, gastric emptying should be performed and general measures for cardiac support and respiratory assistance should be planned. Dilution solution should be infused intravenously to avert the possibility of crystalluria.

The value of dialysis in dantrolene overdose is not known and there is no specific antidote for dantrolene overdose.

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.

  • AgilusDantroleni natricum · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Dantrium 100 mg Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →